|
Sponsor
|
Study ID ↑
|
Description
|
Created
|
| |
|
*ASTELLAS-9463-EC-0002
|
An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-blind Study
|
7/31/2017
|
| |
|
*BAYER-B078
|
Five-year Clinical Performance of the New Formulation of the Levonorgestrel Intrauterine System and Serum Levonorgestrel Concentration with the New Formulation Compared to That with the Original One.
Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: B078, Sponsor: Bayer
|
11/30/2016
|
| |
|
*BI-1123.10
|
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Medicine: tenecteplase, Condition: Myocardial Infarction, Phase: 3, Clinical Study ID: 1123.10, Sponsor: Boehringer Ingelheim
|
9/30/2014
|
| |
|
*BI-1123.11
|
A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting
Medicine: tenecteplase, Condition: Myocardial Infarction, Phase: 3, Clinical Study ID: 1123.11, Sponsor: Boehringer Ingelheim
|
9/30/2014
|
| |
|
*BI-1123.12
|
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
Medicine: tenecteplase, Condition: Myocardial Infarction, Phase: 4, Clinical Study ID: 1123.12, Sponsor: Boehringer Ingelheim
|
9/30/2014
|
| |
|
*BI-1123.18
|
Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial
Medicine: tenecteplase, Condition: Heart Arrest, Phase: 3, Clinical Study ID: 1123.18, Sponsor: Boehringer Ingelheim
|
9/30/2014
|
| |
|
*BI-1123.28
|
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
Medicine: tenecteplase, Condition: Myocardial Infarction, Phase: 3, Clinical Study ID: 1123.28, Sponsor: Boehringer Ingelheim
|
10/26/2015
|
| |
|
*BI-1123.8
|
Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction
Medicine: tenecteplase, Condition: Myocardial Infarction, Phase: 3, Clinical Study ID: 1123.8, Sponsor: Boehringer Ingelheim
|
10/26/2015
|
| |
|
*BI-1208.10
|
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
Medicine: duloxetine hydrochloride, Condition: Depressive Disorder, Major, Phase: 3, Clinical Study ID: 1208.10, Sponsor: Boehringer Ingelheim
|
1/2/2015
|
| |
|
*BI-1208.22
|
A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women >= 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence
Medicine: duloxetine hydrochloride, Condition: Urinary Incontinence, Stress, Phase: 4, Clinical Study ID: 1208.22, Sponsor: Boehringer
|
1/2/2015
|